V. Castel

Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients.

A. Llombart‐Bosch, A. Pellín, S. Navarro, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Precision medicine in Ewing sarcoma: a translational point of view

A. Cañete, P. Gargallo, V. Segura, 2020, Clinical and Translational Oncology.

[The new challenge in oncology: Next-generation sequencing and its application in precision medicine].

L. Pedrola, I. Calabria, D. Sánchez-Izquierdo, 2016 .

Outcome of high-risk neuroblastoma using a dose intensity approach: improvement in initial but not in long-term results.

S. Navarro, A. Cañete, P. García-Miguel, 2001, Medical and pediatric oncology.

Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial.

M. Garami, I. Yaniv, T. Trahair, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial

K. McHugh, N. Fenwick, G. Barone, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[The new challenge in oncology: Next-generation sequencing and its application in precision medicine].

J. Millán, J. Cervera, A. Cañete, 2016 .

High survival rate in infant acute leukemia treated with early high-dose chemotherapy and stem-cell support. Groupo Español de Trasplante de Médula Osea en Niños.

A. Sastre, L. Madero, M. Díaz, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.